To date, no targeted therapies are available to treat triple negative breast cancer (TNBC),
while other breast cancer subtypes are responsive to current therapeutic treatment …

Triple negative breast cancer (TNBC) is a subtype of breast cancer with typically poorer
outcomes due to its aggressive clinical behavior and lack of targeted treatment options …

Cancer cells can exhibit altered dependency on specific metabolic pathways and targeting
these dependencies is a promising therapeutic strategy. Triple-negative breast cancer …

Metabolic dysregulation is a prominent feature in breast cancer, but it remains poorly
characterized in patient tumors. In this study, untargeted metabolomics analysis of triple …

This study aimed to investigate metabolic changes following the acquisition of resistance to
doxorubicin in the triple-negative breast cancer (TNBC) cell line MDA-MB-231. Two drug …

Purpose HER2-enriched breast cancer with high levels of hormone receptor expression,
known as" triple positive" breast cancer, may represent a new entity with a relatively …

Background/Aim: Trastuzumab and tamoxifen are two of the most widely prescribed anti-
cancer drugs for breast cancer (BC). To date, few studies have explored the impact of …

Breast cancer cells MCF-7 and MDA-MB-231 were treated with Tamoxifen (5 μM) or
Paclitaxel (1 μM) or with a combination of the two drugs. Herein, we have employed gas …

Molecular subtyping of breast cancer is necessary for therapy selection and mandatory for
all breast cancer patients. Metabolic alterations are considered a hallmark of cancer and …

Patients with triple-negative breast cancer (TNBC) are unresponsive to endocrine and anti-
HER2 pharmacotherapy, limiting their therapeutic options to chemotherapy. TNBC is …